📋 Weekly Playbook

💊 Drug Overview

Brand: Ocrevus (IV) | Ocrevus Zunovo (SC) Generic: ocrelizumab | ocrelizumab & hyaluronidase-ocsq Class: CD20-directed cytolytic monoclonal antibody Manufacturer: Genentech

✅ FDA-Approved Indications

Both formulations: • Relapsing forms of MS (RMS): CIS, RRMS, active SPMS — adults • Primary progressive MS (PPMS) — adults Only FDA-approved therapy for both RMS and PPMS.

🔬 Mechanism of Action

Selectively targets and depletes CD20-expressing B-cells via antibody-dependent cellular phagocytosis, cellular cytolysis, and complement-mediated lysis. Reduces the B-cell-driven inflammatory activity believed to drive MS progression.

📊 Key Efficacy Data

• RMS: 46–47% reduction in annualized relapse rate vs. Rebif (p<0.0001) • RMS: 40% reduction in 12-week confirmed disability progression vs. Rebif • PPMS: Significantly prolonged time to disability progression vs. placebo (32.9% vs. 39.3%) • Ocrevus Zunovo: Non-inferior to IV Ocrevus in serum ocrelizumab exposure (OCARINA II trial)

👥 Target Patient Population

Adults with relapsing or primary progressive MS. Prescribing specialists: neurologists and MS specialists.

⚠️ Key Safety Considerations

• Infusion/injection reactions: 34–40% incidence (highest on first dose) • Serious infections (bacterial, viral, fungal) — delay if active infection • HBV reactivation risk — screen before initiating • PML risk — withhold at first sign/symptom • Monitor immunoglobulins; potential malignancy risk (breast cancer) • Zunovo: Injection site reactions; abdomen-only administration